# Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

> **NCT01863199** · PHASE4 · COMPLETED · sponsor: **Retinal Consultants of Arizona** · enrollment: 60 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** Lucentis (Treat and extend)
- **DRUG:** Lucentis every 4 weeks
- **DRUG:** Lucentis every 12 weeks

## Key facts

- **NCT ID:** NCT01863199
- **Lead sponsor:** Retinal Consultants of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863199, "Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01863199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*